Thank you FTM for another very useful data set, this time for the liver IST trial being done at UTSMC with Thorpe's home team.
Given that the PR announcing trial initiation was on Dec 1, 2010, this IST will have been running for 16 months when AACR begins next week. ClinicalTrials.gov says December 2012 is the Estimated Primary Completion Date (i.e. final data collection date for primary outcome measures). Thus the trial is now 64% complete, i.e. 16 out of 25 months.
Estimated enrollment in this trial is 56 patients.
Since this is an open-label trial, and since an Abstract about safety data from this trial is being presented at AACR, I think there is a good chance the Company may also elect to put out a PR during AACR week showing interim ORR and TTP data on the first 25 or 30 liver patients, if the data is good.
Based on remarks made by King in recent CCs and Conferences and summarized in a recent C.J. post (help please with C.J.'s Post # ?), it would appear that Bavi plus Sorafenib is generating good results.
How can SK tell already that this interim HCC data is good? Answer: just look at FTM's chart. Historical TTP for Child-Pugh A patients is only 5.5 months. This IST has been running for 16 months. ... Connect the Dots. The Company already knows whether Bavi plus Sorafenib is working in roughly half the trial patients.
News 
Market Data 
Discover 
